The U.S. Food and Drug Administration (FDA) issued new draft guidance on October 29, 2025, proposing what it said were “major updates to simplify biosimilarity studies and reduce unnecessary clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback